VABYSMO: payments to doctors
Payments that named VABYSMO as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $9.4M
- Providers
- 5,591
- Transactions
- 33,552
- Average per transaction
- $279
The per-transaction average — $279 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 5,591 providers the average total is $1,672, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech USA, Inc. | $7,651,582 | 81.8% |
| Genentech, Inc. | $1,121,939 | 12.0% |
| F. Hoffmann-la Roche AG | $284,241 | 3.0% |
| Hoffmann-la Roche Limited | $175,207 | 1.9% |
| Roche Products Limited | $117,527 | 1.3% |